Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries

JAMA Cardiology

Volumn 2, Issue 8, 2017, Pages 890-895

  Colantonio, Lisandro D ^a   Huang, Lei ^a   Monda, Keri L ^b   Bittner, Vera ^c   Serban, Maria Corina ^d   Taylor, Benjamin ^b   Brown, Todd M ^c   Glasser, Stephen P ^e   Muntner, Paul ^a   Rosenson, Robert S ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AMGEN INC   (United States)

^c University of Alabama at Birmingham   (United States)

^d VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e University of Alabama at Birmingham   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AFRICAN AMERICAN; AGED; ARTICLE; CARDIOLOGIST; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG USE; FEMALE; HEART INFARCTION; HEART REHABILITATION; HISPANIC; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CAUCASIAN; ETHNOLOGY; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ATORVASTATIN; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICARE; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM; SECONDARY PREVENTION; UNITED STATES;

EID: 85025431391     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.0911     Document Type: Article

References (15)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
2. SilvaM, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253-260.
3. US Food and Drug Administration. FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury. Silver Springs, MD: US Department of Health & Human Services; 2011.
4. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7): 457-464.
5. Levitan EB, Muntner P, Chen L, et al. Burden of coronary heart disease rehospitalizations following acutemyocardial infarction in older adults. Cardiovasc Drugs Ther. 2016;30(3):323-331.
6. Rosenson RS, Kent ST, Brown TM, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J AmColl Cardiol. 2015;65(3):270-277.
7. Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6):685-698.
8. Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction. JAMA Cardiol. 2016;1(2): 147-155.
9. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5): 472-483.
10. Pedan A, Varasteh L, Schneeweiss S. Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm. 2007;13(6):487-496.
11. Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: A review and case studies. Cardiovasc Drugs Ther. 2014;28(1):99-109.
12. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196-202.
13. Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence aftermyocardial infarction: experience of a community. Am J Med. 2009;122 (10):961. e7-961. e13.
14. Choudhry NK, Avorn J, Glynn RJ, et al; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications aftermyocardial infarction. N Engl J Med. 2011;365(22):2088-2097.
15. Jiang X, Sit JW, Wong TK. A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: evidence from Chengdu, China. J Clin Nurs. 2007;16(10):1886-1897.